GSK's Arexvy Shows Promising RSV Protection Over Three Seasons

GSK's Arexvy RSV vaccine demonstrated 43.3% effectiveness in preventing severe illness in its third trial season, following 94.1% effectiveness initially and 64.2% in the second year. The vaccine, one of three approved, is recommended for adults aged 75+ and those 60-74 at higher risk.

GSK has announced that its Arexvy vaccine for RSV showed a 43.3% effectiveness in preventing severe illness during its third season after administration, a decrease from its initial 94.1% efficacy recorded in the first season, and 64.2% the following year, according to data from its Phase 3 clinical trial.

Arexvy, alongside vaccines produced by Pfizer and Moderna, is approved for use and has been leading the market. In the U.S., the vaccine is recommended for one-time administration to adults aged 75 and older, and for individuals aged 60 to 74 who are considered at higher risk for severe illness.

Tony Wood, GSK's chief scientific officer, expressed enthusiasm about the potential impact of Arexvy, stating that it offers significant protection for older adults over multiple seasons, aiming to enhance public health. GSK continues to provide data to regulators to guide decisions on possible re-vaccination strategies.

(With inputs from agencies.)